BlackRock, Inc. Amends Schedule 13G for Inhibrx Biosciences, Inc.

BlackRock, Inc. has filed an amended Schedule 13G with the SEC, disclosing its ownership of 680,368 shares of Inhibrx Biosciences, Inc., representing 4.7% of the company's common stock. The filing indicates that BlackRock, Inc. has sole voting power over 664,427 shares and sole dispositive power over 680,368 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was filed on October 17, 2025, and reflects the securities beneficially owned by certain business units of BlackRock, Inc. and its subsidiaries and affiliates.